{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:10Z","timestamp":1790720350801,"version":"4.1.0"},"reference-count":39,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,2,3]]},"published-print":{"date-parts":[[2026,6]]},"DOI":"10.2967\/jnumed.125.270202","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:15:15Z","timestamp":1774541715000},"page":"887-894","source":"Crossref","is-referenced-by-count":1,"title":["[\n                    <sup>177<\/sup>\n                    Lu]Lu-DOTATATE Population Pharmacokinetics and Dosimetry Modeling for Adolescent and Adult Patients with Somatostatin ReceptorPositive Gastroenteropancreatic Neuroendocrine Tumors"],"prefix":"10.2967","volume":"67","author":[{"given":"Meemansa","family":"Sood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Lachi Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yun","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Blumenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzeddine","family":"Cherfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Khanshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026060105301043000_67.6.887.1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep."},{"key":"2026060105301043000_67.6.887.2","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/cancers14061428","article-title":"Health-related quality of life (HRQoL) in neuroendocrine tumors: a systematic review","volume":"14","author":"Gosain","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2026060105301043000_67.6.887.3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"2026060105301043000_67.6.887.4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12885-023-10567-1","article-title":"What have we learnt from the past: would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?","volume":"23","author":"Stiefel","year":"2023","journal-title":"BMC Cancer."},{"key":"2026060105301043000_67.6.887.5","doi-asserted-by":"crossref","first-page":"e13310","DOI":"10.1111\/jne.13310","article-title":"Global challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients","volume":"35","author":"Dureja","year":"2023","journal-title":"J Neuroendocrinol."},{"key":"2026060105301043000_67.6.887.6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5057-3"},{"key":"2026060105301043000_67.6.887.7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00432-023-05568-3","article-title":"Gastroenteropancreatic neuroendocrine carcinoma in children and adolescents: a population-based study","volume":"150","author":"Lin","year":"2024","journal-title":"J Cancer Res Clin Oncol."},{"key":"2026060105301043000_67.6.887.8","doi-asserted-by":"crossref","first-page":"17588359231156218","DOI":"10.1177\/17588359231156218","article-title":"A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors","volume":"15","author":"Donadio","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2026060105301043000_67.6.887.9","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050034"},{"key":"2026060105301043000_67.6.887.10","doi-asserted-by":"publisher","DOI":"10.1385\/MO:20:1:59"},{"key":"2026060105301043000_67.6.887.11","unstructured":"Lutathera. Annex I: summary of product characteristics. European Medicines Agency website. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lutathera-epar-product-information_en.pdf. Annex I. Published September 2017. Accessed September 20, 2024."},{"key":"2026060105301043000_67.6.887.12","unstructured":"Lutathera. Highlights of prescribing information. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208700s019s023lbl.pdf. Revised June 2022. Accessed September 25, 2024."},{"key":"2026060105301043000_67.6.887.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2026060105301043000_67.6.887.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"2026060105301043000_67.6.887.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2026060105301043000_67.6.887.16","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1007\/s00259-022-05771-3","article-title":"Efficacy and safety of 177Lu-DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study","volume":"49","author":"Clement","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301043000_67.6.887.17","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"key":"2026060105301043000_67.6.887.18","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100574"},{"key":"2026060105301043000_67.6.887.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0778-1"},{"key":"2026060105301043000_67.6.887.20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/0284186X.2017.1378431","article-title":"Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance","volume":"57","author":"Sandstrom","year":"2018","journal-title":"Acta Oncol."},{"key":"2026060105301043000_67.6.887.21","doi-asserted-by":"crossref","first-page":"e29056","DOI":"10.1002\/pbc.29056","article-title":"Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children","volume":"68","author":"Foster","year":"2021","journal-title":"Pediatr Blood Cancer."},{"key":"2026060105301043000_67.6.887.22","doi-asserted-by":"crossref","first-page":"1193880","DOI":"10.3389\/fnume.2023.1193880","article-title":"Case report: peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors","volume":"3","author":"Hlongwa","year":"2023","journal-title":"Front Nucl Med."},{"key":"2026060105301043000_67.6.887.23","unstructured":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT04711135A. Published August 31, 2022. Accessed September 20, 2024."},{"key":"2026060105301043000_67.6.887.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0761-x"},{"key":"2026060105301043000_67.6.887.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3193-4"},{"key":"2026060105301043000_67.6.887.26","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2026060105301043000_67.6.887.27","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00259-017-3688-2","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study","volume":"44","author":"Del Prete","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301043000_67.6.887.28","first-page":"134","article-title":"Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy","volume":"48","author":"Konijnenberg","year":"2007","journal-title":"J Nucl Med."},{"key":"2026060105301043000_67.6.887.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3001-1"},{"key":"2026060105301043000_67.6.887.30","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1214\/17-EJS1337SI","article-title":"Sparsity information and regularization in the horseshoe and other shrinkage priors","volume":"11","author":"Piironen","year":"2017","journal-title":"Electron. J. Statist."},{"key":"2026060105301043000_67.6.887.31","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1007\/s00259-025-07246-7","article-title":"Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: primary analysis of the phase II NETTER-P study","volume":"52","author":"Gaze","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301043000_67.6.887.32","unstructured":"General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products: Guidance for Industry. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/general-clinical-pharmacology-considerations-pediatric-studies-drugs-including-biological-products. Updated September 7, 2022."},{"key":"2026060105301043000_67.6.887.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0820-3"},{"key":"2026060105301043000_67.6.887.34","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1097\/RLU.0000000000005233","article-title":"Safety and efficacy of 177Lu-DOTATATE in children and young adult population: a single-center experience","volume":"49","author":"Aggarwal","year":"2024","journal-title":"Clin Nucl Med."},{"key":"2026060105301043000_67.6.887.35","first-page":"242155","article-title":"177Lu-DOTATATE kidney absorbed doses correlate with renal function at 9 months after treatment [abstract]","volume":"65","author":"Kayal","year":"2024","journal-title":"J Nucl Med."},{"key":"2026060105301043000_67.6.887.36","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263056"},{"key":"2026060105301043000_67.6.887.37","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21695"},{"key":"2026060105301043000_67.6.887.38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2021.06.050","article-title":"Late-onset kidney failure in survivors of childhood cancer: a report from the childhood cancer survivor study","volume":"155","author":"Dieffenbach","year":"2021","journal-title":"Eur J Cancer."},{"key":"2026060105301043000_67.6.887.39","unstructured":"Lutathera. Highlights of Prescribing Information. U.S. Food and Drug Administration website. April 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208700s031lbl.pdf. Revised April 2024. Accessed September 25, 204."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:19:03Z","timestamp":1785269943000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.2967\/jnumed.125.270202"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270202","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}